

APR 12 2002

élan diagnostics



K020575

SUMMARY OF 510(K) SAFETY AND EFFECTIVENESS INFORMATION

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The ATAC Direct LDL Reagent Kit, the ATAC Direct LDL Calibrator and the ATAC 8000 Random Access Chemistry System are intended for use as a system for the quantitative determination of LDL-cholesterol in serum and plasma. LDL-cholesterol results are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases, and for the assessment of the risk of developing cardiovascular disease.

The ATAC Direct LDL Reagent determines LDL-cholesterol through a two step reaction, which depends on the special properties of the detergent. In the first step, non-LDL sources of cholesterol are consumed in a series of reactions without producing color. In the second reaction step, the chromogen is added, and a second detergent solubilizes the LDL-cholesterol, which is now available to react with cholesterol oxidase, cholesterol esterase and peroxidase in the reagent to produce a color that is proportional to the amount of LDL-cholesterol in the sample.

The ATAC Direct LDL Reagent Kit, calibrated with the ATAC Direct LDL Calibrator, is substantially equivalent to the N-geneous LDL Cholesterol Reagent Kit, product no. 80-4598-00, calibrated with N-geneous LDL Cholesterol Calibrator, product no. 80-4610-02, which are currently marketed by Genzyme Corporation of Cambridge, MA.

The effectiveness of ATAC Direct LDL Reagent Kit and the ATAC Direct LDL Calibrator used on the ATAC 8000 Random Access Chemistry System is shown by the following studies.

The recovery of LDL-cholesterol using the ATAC Direct LDL Reagent is linear from 5 to 700 mg/dL as shown by the recovery of linearity standards that span the usable range. Linear regression statistics, with the regression line forced through the origin, compare standard recoveries to standard factors.

(ATAC Recoveries) = 0 mg/dL + 1.023 x (Standard Factors), r = 0.9996, sy.x = 7.8 mg/dL, n = 35

Precision is demonstrated by the replicate assay of commercially available control serum and a serum pool. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below.

Sample	n	mean	Precision of LDL-Cholesterol Recoveries in mg/dL			Total %CV
			Within Run		1SD	
			1SD	%CV	1SD	
Serum 1	60	93	1.4	1.5%	2.7	2.9%
Serum 2	60	184	3.3	1.8%	4.9	2.7%
Serum 3	59	555	11.9	2.2%	19.2	3.5%

Mixed serum and plasma specimens, collected from adult patients, were assayed for LDL cholesterol using the ATAC 8000 Random Access Chemistry System and another commercially available method. Results were compared by least squares linear regression and the following statistics were obtained.

Serum/Plasma Comparison

ATAC 8000 = -1.7 mg/dL + 1.078 x Competitive Reagent  
r = 0.996 n = 159 range = 19 - 265 mg/dL

To verify accuracy, 42 serum and plasma specimens, collected from 22 adults were assayed for LDL cholesterol using the ATAC 8000 Random Access Chemistry System and the beta-quantification reference method. Results were compared by least squares linear regression and the following statistics were obtained.


Serum/Plasma Comparison

$$\text{ATAC 8000} = -4.2 \text{ mg/dL} + 1.035 \times \text{reference method}$$

$r = 0.986$      $n = 42$      $\text{range} = 59 - 178 \text{ mg/dL}$

The detection limit claim of 5 mg/dL is documented through the repetitive assay of a diluted serum pool. The observed detection limit, calculated as two standard deviations of a 30 replicate within run precision study, is 0.73 mg/dL and is below the claimed limit.

The 14 day on board reagent stability and 14 day calibration stability claims are documented through the assay of serum controls over the claimed periods. In all cases, the total imprecision of LDL-cholesterol recoveries over the test periods are less than 3%.



Wynn Stocking  
Manager of Regulatory Affairs  
Elan Diagnostics



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

APR 12 2002

Mr. Wynn Stocking  
Manager, Regulatory Affairs  
Elan Diagnostics  
1075 W. Lambert Road, Building D  
Brea, California 92821

Re: k020575  
Trade/Device Name: ATAC Direct LDL Reagent and ATAC Direct LDL Calibrator  
Regulation Number and Name: 21 CFR § 862.1475-Low density lipoprotein test system  
Regulation Number and Name: 21 CFR § 862.1150-Calibrator, secondary  
Regulatory Class: I Product Code: MRR  
Regulatory Class: II Product Code: JIT  
Dated: February 20, 2002  
Received: February 21, 2002

Dear Mr. Stocking:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K020575

Device Name: ATAC Direct LDL Reagent and ATAC Direct LDL Calibrator

Indications For Use:

The ATAC Direct LDL Reagent Kit, the ATAC Direct LDL Calibrator and the ATAC 8000 Random Access Chemistry System are intended for use as a system for the quantitative determination of LDL-cholesterol in serum and plasma. LDL-cholesterol results are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases, and for the assessment of the risk of developing cardiovascular disease.

This reagent is intended to be used by trained personnel in a professional setting and is not intended for home use.

Respectfully,

*Wynn Stocking*  
Wynn Stocking  
Regulatory Affairs Manager  
Elan Diagnostics

20 February, 2002

*Alan Coogan*  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K020575

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use   
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)